1Abdel-Meguid TA.Botulinum toxin-A injections into neurogenic overactive bladder-to include or exclude the trigone?A prospective,randomized,controlled trial. Journal d Urologie . 2010 被引量：1
2Kobayashi S,Ikeda K,Miyata K.Comparison of in vitro selectivi-typrofiles of solifenacin succinate (YM905)and current antimus-carinicdrugs in bladder and salivary glands:a Ca2+mobilization-study in monkey cells. Life Sciences . 2004 被引量：1
3Wein AJ,Rovner ES.Definition and epidemiology of overactive bladder. Urology . 2002 被引量：1
4Buyse G,Verpoorten C,Vereecken R,et al.Intravesical application of a stable oxybutynin solution improves therapeutic compliance and acceptance in children with neurogenic bladder dysfunction. Journal d Urologie . 1998 被引量：1
5Andersson K E.New pharmacologic targets for the treatment of the overactive bladder:an update. Urology . 2004 被引量：1
1Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function, report from the standardisaton subcommittee of the International Continence Society. Neurourol Urodyn, 2002, 21: 167-178. 被引量：1
2Rovner ES, Wein AJ. Incidence and prevalence of overactive bladder. Curr Urol Rep, 2002, 3:434- 438. 被引量：1
3Irwin DE, Milsom I, Kopp Z, et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int, 2006, 97: 96-100. 被引量：1
5Ikeda K, Kobayashi S, Suzuki M, et al. M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. N-S Arch Pharmacol, 2002, 366: 97-103. 被引量：1
6Ohtake A, Ukai M, Hatanaka T, et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmaeol, 2004, 492:243- 250. 被引量：1
7Kobayashi S, Ikeda K, Miyata K. Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells. Life Sci, 2004, 74: 843-853. 被引量：1
8Smulders RA, Krauwinkel WJ, Swart PJ, et al. Pharmacokinetics and safety of solifenacin succinate in healthy young men. J Clin Pharmacol, 2004, 44:1023- 1033. 被引量：1
9Chapple CR, Arano P, Bosch JL, et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int, 2004, 93: 71-77. 被引量：1
9Cartwright R, Cardozo L. Transdermal oxybutynin: stick- ing to the facts[J]. Eur Urol, 2007,51 (4) : 907. 被引量：1
10Howard R, Schmid B, Feick A, et al. Oxybutynin enantio- mer pharmaceutics following oral and transdermal deliv- eIy[J].Pharmaceutical Research, 2001,18 (7) : 1 029. 被引量：1
